

9th Haemophilia Global Summit

27–29th September 2018, Vienna, Austria

This meeting is initiated and funded by Pfizer
An independent faculty determined the
structure and scientific content of the meeting

Thursday 27th September 2018

Arrivals, Dinner and Keynote Address

Friday 28th September 2018

08:30	Welcome and introduction
SESSION 1: CLINICAL CONSIDERATIONS IN GLOBAL HAEMOPHILIA CARE	
08:45	Plenary: Towards zero bleeds in haemophilia care: an achievable goal today?
09:15	Masterclass: Orthopaedic considerations in haemophilia: focus on the ankle
09:45	Masterclass: Optimising approaches to pain management in haemophilia: practical considerations
10:15	Plenary: Psychosocial aspects of haemophilia care in the early years
10:45	<i>Coffee break</i>
SESSION 2: HOT TOPICS IN HAEMOPHILIA INHIBITOR MANAGEMENT	
11:15	Debate: “Immune tolerance induction (ITI) therapy should continue to be first-line treatment for inhibitor patients” (For / Against)
12:00	Masterclass: Surgical management of inhibitor patients: now and in the future
12:30	<i>Lunch</i>
SESSION 3: PRACTICAL MANAGEMENT OF HAEMOPHILIA	
14:00	Parallel workshop sessions (<i>please see last page</i>)
15:00	Parallel workshop sessions (<i>please see last page</i>)
16:00	<i>Coffee break</i>
SESSION 4: RESEARCH IN HAEMOPHILIA CARE	
16:15	Oral presentations: ASPIRE scientific research <i>We are delighted to welcome previous participants in the ASPIRE (Advancing Science through Pfizer Investigator Research Exchange) grant programme to present their work</i>
17:00	<i>Day 1 closing remarks</i>

Details of the global faculty will be available shortly

Steering Committee

The scientific content and structure of this meeting has been determined by an independent Steering Committee:
Jan Astermark (Sweden), Jan Blatný (Czech Republic), Gerry Dolan (UK), Cedric Hermans (Belgium), Ingrid Pabinger-Fasching (Austria)

Saturday 29th September 2018

SESSION 5: HOT TOPICS IN BLEEDING DISORDERS – SLAM SESSION

The SLAM session is designed as a series of rapid-fire presentations with the aim of providing succinct updates on current and future hot topics in haemophilia care. Each presenter will provide a snapshot of their topic, followed by questions from the audience.

- 08:30
1. Approaches to the management of PUPs and neonates with haemophilia B
 2. Gynaecological considerations in haemophilia carriers
 3. Inhibitor management in mild and moderate haemophilia
 4. The role of holistic management in acquired haemophilia
 5. Optimising low-dose prophylaxis in resource-limited countries
 6. Age-related comorbidities in people with haemophilia: acute management of unstable angina and myocardial ischaemia

10:00 **Masterclass:** Spotlight on “other” bleeding disorders: Glanzmann's thrombasthenia

10:30 *Coffee break*

SESSION 6: FUTURE PERSPECTIVES IN HAEMOPHILIA CARE

11:00 **Masterclass:** Reimbursement models for novel therapies: the pharmacoeconomics of choice

11:30 **Plenary:** Non-factor-based approaches to haemophilia care: spotlight on anti-TFPI

12:00 **Plenary:** Understanding the science of gene therapy for haemophilia

12:30 **Masterclass:** Current and future considerations in gene therapy for haemophilia: paediatric considerations

13:00 **Plenary:** Beyond gene therapy: introduction to CRISPR genome editing technology

13:30 *Lunch and departures*

PUPs: Previously untreated patients; TFPI: Tissue factor pathway inhibitor; CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats.

Details of the global faculty will be available shortly

Steering Committee

The scientific content and structure of this meeting has been determined by an independent Steering Committee:
Jan Astermark (Sweden), Jan Blatný (Czech Republic), Gerry Dolan (UK), Cedric Hermans (Belgium), Ingrid Pabinger-Fasching (Austria)

9th Haemophilia Global Summit

27–29th September 2018, Vienna, Austria

This meeting is initiated and funded by Pfizer
An independent faculty determined the
structure and scientific content of the meeting

Workshop sessions: Friday 28th September 2018

You will have the opportunity to attend two of the six workshops below.
Please make your selections at the time of registration.

SESSION 3: PRACTICAL MANAGEMENT OF HAEMOPHILIA

- A** Practical guide to population pharmacokinetics in haemophilia
- B** Understanding assays in practice: laboratory pitfalls in haemophilia diagnosis and follow-up
- C** Optimising joint health outcomes in clinical practice: practical guide to HJHS and imaging modalities
- D** Global perspectives of haemophilia care: collaborative case studies
- E** Scientific publishing: practical instruction and tips for success
- F** Understanding the value of genetics and genetic testing in haemophilia care

HJHS: Haemophilia Joint Health Score.

Details of the global faculty will be available shortly



Steering Committee

The scientific content and structure of this meeting has been determined by an independent Steering Committee:
Jan Astermark (Sweden), Jan Blatný (Czech Republic), Gerry Dolan (UK), Cedric Hermans (Belgium), Ingrid Pabinger-Fasching (Austria)